Innovation has developed two lead drug candidates—each with first-in-class potential across multiple clinical indications attributable to novel mechanisms of action—with dermatology, anti-inflammatory, antibiotic and oncology applications.

  • Brilacidin—an immunomodulatory agent with anti-inflammatory/antibiotic properties

  • Kevetrin—a non-genotoxic anti-cancer drug that modulates p53

Based on sound science, and covered by strong intellectual property and patent protections, these drug candidates are in mid-to-late stage clinical trials.

Advancing under a number of special FDA designations to help expedite development, improve likelihood of drug approval and gain market exclusivity, they address large areas of unmet medical need and represent sizable commercial opportunities.

Click here (pdf) for a Corporate Overview of Innovation Pharmaceuticals.